Ovarian Endometrioid Adenocarcinoma with Functioning Stroma Accompanied with Endometrial Endometrioid Adenocarcinoma: Immunohistochemical Study and Literature Review

Takashi Yuri, Tomomi Mizokami, Yuichi Kinoshita, Katsuhiko Yoshizawa, Katsuhiko Yasuda, Airo Tsubura

.
Department of Pathology II, Kansai Medical University, Divisions of Obsterics and Gynecology, Kansai Medical University, Osaka, Japan.

DOI: 10.4236/ojpathology.2013.34028                

Abstract

Background: The ovarian tumors with functioning stroma are defined by the morphological presence of endocrine active cells in stroma, and the clinical, biochemical or pathological evidence of endocrine function. Case Report: The ovarian endometrioid adenocarcinoma with functioning stroma accompanied with endometrial endometrioid adenocarcinoma was found in 64-year-old post-menopausal woman complaining abnormal genital bleeding and mammary distention. Her preoperative serum 17?-estradiol level was high (53.2 pg/ml) while human chorionic gonadotropin (hCG) level was within normal limit. Her right ovary with 8.8 × 5.3 cm in size and tan-yellow in color mostly consisted of solid tumor. Histologically, tumor was composed of estrogen receptor (ER)- and progesterone receptor (PgR)-positive, and androgen receptor (AR)-negative cancerous endometrial cells with aggregates of vacuolated foamy stromal cells resembling luteinized cells. These stromal cells contained lipid droplets, and was immunopositive for α-inhibin and 17?-estradiol. After surgery, serum 17?-estradiol level decreased and became normal (14.2 pg/ml). These findings indicate the production of steroid hormone (17?-estradiol) from the foamy stromal cells and may be correlated with the clinical symptoms. Furthermore, ER- and PgR-positive endometrial endometrioid adenocarcinoma developed synchronously. However, ovary and uterus were totally immunonegative for human chorionic gonadotropin (hCG). Four other cases from the literature including ours are reviewed. Conclusion: Cancer cells were positive for ER and PgR in both ovary and uterus responded to steroid hormone produced by foamy stromal cells, which played a role in proliferation and progression of ovarian and endometrial endometrioid adenocarcinoma, respectively.

Keywords

Ovarian Cancer; Endometroid Adenocarcinoma; Functioning Stroma; Immunohistochemistry; Estrogen; Etradiol

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	K. Gajjar, G. Ogden, M. I. Mujahid and K. Razvi, “Symptoms and Risk Factors of Ovarian Cancer: A Survey in Primary Care,” International Scholarly Research Network Obstetrics and Gynecology, 2012, Article ID: 754197.
[2]	J. M. Morris, R. E. Scully, “Endocrine Pathology of the Ovary,” CV Mosby, St. Louis, 1958, pp. 131-139.
[3]	J. L. Rutgers and R. E. Scully, “Functioning Ovarian Tumors with Peripheral Steroid Cell Proliferation; a Report of Twenty-Four Cases,” International Journal of Gynecological Pathology, Vol. 5, No. 4, 1986, pp. 319-337. http://dx.doi.org/10.1097/00004347-198612000-00004
[4]	F. A. Tavassoli, “Ovarian Tumors with Functioning Manifestations,” Endocrine Pathology, Vol. 5, No. 3, 1994, pp. 137-148. http://dx.doi.org/10.1007/BF02921469
[5]	Y. O. Tanaka, H. Tsunoda, Y. Kitagawa, T. Ueno, H. Yoshikawa and Y. Saida, “Functioning Ovarian Tumors: Direct and Indirect Findings at MR Imaging,” Radiographics, Vol. 24, Suppl. 1, 2004, pp. S147-S166. http://dx.doi.org/10.1148/rg.24si045501
[6]	N. Takai, K. Kai, A. Tsumo, K. Nasu, K. Kashima and H. Narahara, “Synchronous Ovarian Endometrioid Adenocarcinoma with a Functioning Stroma and Endometrial Endometrioid Adenocarcinoma by Different Loss of Heterozygosity Findings,” Archives of Gynecology and Obsterics, Vol. 284, 2010, pp. 951-955.
[7]	T. M. Ulbright and L. M. Roth, “Metastatic and Independent Cancers of the Endometrium and Ovary: A Clinicopathologic Study of 34 Cases,” Human Pathology, Vol. 16, No. 1, 1985, pp. 28-34. http://dx.doi.org/10.1016/S0046-8177(85)80210-0
[8]	C. C. van Niekerk, J. Bulten, G. P. Vooijs and A. L. Verbeek, “The Association between Primary Endometrioid Carcinoma of the Ovary and Synchronous Malignancy of the Endometrium,” Obsterics and Gynecology Intenational, 2010, Article ID: 465162.
[9]	R. E. Scully, R. H. Young and P. B. Clement, “AFIP Tumors with Functioning Stroma, Atlas of Tumor Pathology, 3rd Series, Tumors of the Ovary, Maldevelopment Gonads, Fallopian Tube, and Broad Ligament,” Washington DC, 1998, pp. 373-378.
[10]	R. E. Scully, R. H. Young and P. B. Clement, “AFIP Tumors with Functioning Stroma, Atlas of Tumor Pathology, 3rd Series, Tumors of the Ovary, Maldevelopment Gonads, Fallopian Tube, and Broad Ligament,” Washington DC, 1998, pp. 107-128.
[11]	M. Farber, P. R. Daoust and J. Rogers, “Hyperthecosis Syndrome,” Obsterics and Gynecology, Vol. 44, 1974, pp. 35-41.
[12]	T. J. Pelkey, H. F. Frierson Jr., S. E. Mills and M. H. Stoler, “The Diagnostic Utility of Inhibin Staining in Ovarian Neoplasms,” International Journal of Gynecological Pathology, Vol. 17, No. 2, 1998, pp. 97-105. http://dx.doi.org/10.1097/00004347-199804000-00001
[13]	C. R. Stewart, M. D. Jeffers and A. Kennedy, “Diagnostic Value of Inhibin Immunoreactivity in Ovarian Gonadal Stromal Tumours and Their Histological Mimics,” Histopathology, Vol. 31, No. 1, 1997, pp. 67-74. http://dx.doi.org/10.1046/j.1365-2559.1997.5780819.x
[14]	E. Kemmann, D. Orenstein, R. M. Shelden and J. R. Jones, “Estrogenization in Women with Postmenopausal Ovarian Hyperthecosis,” International Journal of Gynaecology and Obsterics, Vol. 18, 1980, pp. 188-191.
[15]	J. Aiman, C. D. Edman, F. R. Worley, F. Vellios and P. C. MacDonald, “Androgen and Estrogen Formation in Women with Ovarian Hyperthecosis,” Obsterics and Gynecology, Vol. 51, 1978, pp. 1-9.
[16]	Y. Kurihara, K. Kasahara, H. Sasano, Y. Tsutsumi, “Ovarian Endometrioid Adenocarcinoma Associated with Steroidogenic Foamy Stromal Cells,” Pathology International, Vol. 47, No. 12, 1997, pp. 883-888. http://dx.doi.org/10.1111/j.1440-1827.1997.tb03722.x
[17]	N. Antoniou, M. Varras, Ch. Akrivis, A. Demou, A. Bellou and S. Stefanaki, “Mucinous Cystadenoma of the Ovary with Functioning Stroma and Virilization in Pregnancy: A Case Report and Review of the Literature,” Clinical and Experimental Obsterics and Gynecology, Vol. 30, 2003, pp. 248-252.
[18]	F. Bolat, A. Parlakgumus, T. Canpolat and I. Tuncer, “Benign Mucinous Cystadenoma with Stromal Luteinization Responsible for Maternal Virilization and Fetal Intrauterine Growth Restriction,” Journal of Obsterics and Gynaecology Research, Vol. 37, No. 7, 2011, pp. 893-896. http://dx.doi.org/10.1111/j.1447-0756.2010.01406.x
[19]	X. Matias-Guiu and J. Prat, “Ovarian Tumors with Functioning Stroma. An Immunohistochemical Study of 100 Cases with Human Chorionic Gonadotropin Monoclonal and Polyclonal Antibodies,” Cancer, Vol. 65, No. 9, 1990, pp. 2001-2005. http://dx.doi.org/10.1002/1097-0142(19900501)65:9<2001::AID-CNCR2820650920>3.0.CO;2-7
[20]	H. Tokunaga, J. Akahira, T. Suzuki, T. Moriya, H. Sasano, K. Ito and N. Yaegashi, “Ovarian Epithelial Carcinoma with Estrogen-Producing Stroma,” Pathology International, Vol. 57, No. 5, 2007, pp. 285-290. http://dx.doi.org/10.1111/j.1440-1827.2007.02099.x
[21]	T. Hayasaka, K. Nakahara, T. Kojimahara, M. Saito-Sekiguchi, T. Motoyama and H. Kurachi, “Endometrioid Adenocarcinoma with a Functioning Stroma,” Journal of Obsterics and Gynaecology Research, Vol. 33, No. 3, 2007, pp. 381-383. http://dx.doi.org/10.1111/j.1447-0756.2007.00541.x
[22]	R. Fienberg, “The Stromal Theca Cells and Postmenopausal Endometrial Adenocarcinoma,” Cancer, Vol. 24, No. 1, 1969, pp. 32-37. http://dx.doi.org/10.1002/1097-0142(196907)24:1<32::AID-CNCR2820240104>3.0.CO;2-I
[23]	A. Misir and M. Sur, “Sertoliform Endometrioid Carcinoma of the Ovary. A Potential Diagnostic Pitfall,” Archives of Pathology and Laboratory Medicine, Vol. 131, 2007, pp. 979-981.
[24]	J. Ordi, D. P. Schammel, L. Rasekh and F. A. Tavassoli, “Sertoliform Endometrioid Carcinomas of the Ovary: A Clinicopathologic and Immunohistochemical Study of 13 Cases,” Modern Pathology, Vol. 12, No. 10, 1999, pp. 933-940.